Literature DB >> 30320025

The Prevalence of virB2 and 16SrRNA Genes of Brucella Isolated from Clinical Samples of Hospitals, Western Iran.

Rahim Sorouri1, Shoaib Khadamoradi1, Azad Khaledi2,3, Amir Hossein Abadi1, Davoud Esmaeili1.   

Abstract

Entities:  

Year:  2018        PMID: 30320025      PMCID: PMC6174050     

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.429


× No keyword cloud information.

Dear Editor-in-Chief

Brucellosis is a zoonotic disease and its incidence arises in most cases from a direct or indirect contact with infected animals. Brucellosis is an occupational disease that often threatens ranchers, veterinarians, slaughterhouse workers, and laboratory personnel (1). Prior to 2001, in order to identify Brucella in patients, biochemical tests were used. Then B. abortus16SrRNA was used as a detection method for Brucella in 2001 by determining the variable sequences of these molecules that were specific markers for genus or species (2). The disadvantages of detection methods using culture and biochemical tests are the seven-day time for the result, and also the risk relating to working with Brucella in vitro. However, these complications were resolved using the sequence analysis of 16SrRNA (3). Operon VirB constitutes the Type IV secretory system (T4SS) which has an important role in the proliferation of intracellular bacteria and is one of the significant virulence factors of Brucella. VirB operon is required for intracellular growth and creating infection (4). Among the components of the operon virB, VirB 2 protein has attracted more attention. It is located on the bacterial surface and provides a channel for proteins or factors secreted by the bacterium in an external environment (5). No evidence is available about the frequency of virB2 in Brucella spp., and the importance of this protein in the operon virB. So, we aimed to evaluate the prevalence of genes; virB2 and 16SrRNA of Brucella in clinical samples achieved from hospitals in the west of Iran. One hundred serum samples were collected from patients referred and admitted to hospitals of the Kermanshah Province, western Iran in 2014. These samples were positive as for Wright test (>1/80). Sequences of the virB2 gene and 16SrRNA were obtained from the NCBI and the primers designed using proper software. The primers sequences were as follows: F-16s: 5-CAGAGTGCAATCCGAACTGA-3, R-16s: 5-CAGCTCGTGTCGTGAGATGT-3, F-virb2: 5-TCTTGGATCCCATCTTCAGG-3, R-virb2: 5-GGGCTTCAATCCTTATGCAA-3. The PCR technique in this study is as follows: primary denaturation: 94 °C for 5 min, denaturation at 90 °C for 1 min, annealing at 58 °C for 1 min, extension step: 72 °C for 1 min, 35 cycles and final extension: 72 °C for 5 min. A Commercial DNA kit (Cinnagen Company) was used for extracting DNA from the serum samples. PCR was performed according to the guidelines. Finally, for evaluating the PCR results, electrophoresis was carried out. The data were analyzed using the SPSS software (Version 18; SPSS Inc., Chicago, USA). Among 100 clinical isolates of Brucella, 37 cases (37%) had 16srRNA gene and 33 isolates (33%) had virB2 gene (Fig. 1). In this investigation, 33% of Brucella isolates contained the virB2 gene. This finding leads to the conclusion that the secretory system has a role in intracellular survival and chronic infection. Today, one of the problems in the treatment of chronic Brucella infection comes from a lack of accurate identification in the laboratory by serological tests.
Fig. 1:

Left image; Results of products electrophoresis with 16SrRNA primers. Wells 1–5. Examples of positive samples for 16SrRNA gene and well 6 are related to DNA marker 100bp. Right image; Results of products electrophoresis with virB2 primers. Wells 1, 2 and 3 are examples of positive samples for virB2 gene, well 4 shows the negative control and the well 5 is related to DNA marker 100bp

Left image; Results of products electrophoresis with 16SrRNA primers. Wells 1–5. Examples of positive samples for 16SrRNA gene and well 6 are related to DNA marker 100bp. Right image; Results of products electrophoresis with virB2 primers. Wells 1, 2 and 3 are examples of positive samples for virB2 gene, well 4 shows the negative control and the well 5 is related to DNA marker 100bp The merit of this research lies in the fact that virB2 is considered as a candidate for identification of T4SS system of Brucella isolates. The other good characteristic of this research is that the frequency of this gene is determined from 100 clinical samples. This study investigated for the first time the role played by the T4SS in serum samples. In order to specific study of Brucella, virB2 gene should be used concurrently of specific gene and it’s sequencing together 16SrRNA. This study used for the first time the virB2 gene for diagnosis of Brucella in the serum. Thus, the virB2 gene can be used as a diagnostic factor along with other components.
  4 in total

1.  16S rRNA gene sequence analysis of a Brucella melitensis infection misidentified as Bergeyella zoohelcum.

Authors:  Nihar Dash; Debadatta Panigrahi; Mansour Al-Zarouni; Sanjeet Mishra
Journal:  J Infect Dev Ctries       Date:  2012-03-12       Impact factor: 0.968

Review 2.  The structural biology of type IV secretion systems.

Authors:  Rémi Fronzes; Peter J Christie; Gabriel Waksman
Journal:  Nat Rev Microbiol       Date:  2009-10       Impact factor: 60.633

3.  16S rRNA and omp31 gene based molecular characterization of field strains of B. melitensis from aborted foetus of goats in India.

Authors:  Ajay Singh; Vivek Kumar Gupta; Amit Kumar; Vikas Kumar Singh; Shivasharanappa Nayakwadi
Journal:  ScientificWorldJournal       Date:  2013-12-18

4.  The abcEDCBA-Encoded ABC Transporter and the virB Operon-Encoded Type IV Secretion System of Brucella ovis Are Critical for Intracellular Trafficking and Survival in Ovine Monocyte-Derived Macrophages.

Authors:  Auricelio A Macedo; Ana P C Silva; Juliana P S Mol; Luciana F Costa; Luize N N Garcia; Marcio S Araújo; Olindo A Martins Filho; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.